🇺🇸 FDA
Pipeline program

APR-246

APR-246-01

Phase 1 small_molecule completed

Quick answer

APR-246 for Hematologic Neoplasms is a Phase 1 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aprea Therapeutics
Indication
Hematologic Neoplasms
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials